1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Species | Human |
| Cat.No | ABC-TC0886 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
OVSAHO is a permanent epithelial ovarian carcinoma cell line derived from the abdominal metastatic tumor of a 56-year-old Japanese female with high-grade serous adenocarcinoma. The original tissue was a solid tumor from the ovary, making OVSAHO a widely used model in ovarian cancer research. These cells grow adherently in monolayer culture and display epithelial morphology with a moderately polygonal shape. OVSAHO cells express a variety of cytokeratins including CK6, CK7, CK8, CK14, CK15/16, CK18, and CK19. Cytogenetic analysis reveals a complex karyotype, and they harbor a TP53 nonsense mutation (c.1024C>T; p.Arg342Ter), while retaining wild-type BRCA1. The cells are tumorigenic in both immunodeficient and immunocompetent mice, forming tumors via subcutaneous, intraperitoneal, and orthotopic injection, but show no evidence of metastasis. They are HPV- and EBV-negative. This cell line offers a reliable preclinical platform for investigating serous ovarian carcinoma and p53-related pathways.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The OVSAHO cell line is widely used in ovarian cancer research. As one of the frequently employed tumor models, it important for in vitro screening of experimental anticancer agents. Researchers can rely on OVSAHO to explore specific histologic subtypes and the response to various agents. Additionally, OVSAHO’s utility extends to xenograft models, where supports xenograft-based preclinical drug testing, contributing to the advancement of ovarian cancer treatment strategies.
